Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXYBOND vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Primarily hepatic via CYP3A4 and to a lesser extent CYP2D6. Oxycodone is metabolized to noroxycodone (via CYP3A4), oxymorphone (via CYP2D6), and other minor metabolites.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Approximately 20–30%, primarily to albumin.
>99% bound to albumin; saturable at high concentrations.
2.6–4.0 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, liver).
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Oral: 10–20% (extensive first-pass metabolism); intranasal: 30–50%; intravenous: 100%.
Oral: ~95%; immediate-release formulation.
For GFR 30-59 m L/min: reduce dose by 25% and increase dosing interval. For GFR <30 m L/min: reduce dose by 50% and administer every 12 hours. Avoid in ESRD.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and increase interval. Child-Pugh Class C: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Weight-based dosing: 0.1-0.2 mg/kg/dose every 4-6 hours as needed. Maximum single dose: 5 mg for <50 kg, 10 mg for ≥50 kg.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Start at lowest effective dose (2.5-5 mg every 4-6 hours). Titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor renal function.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression; Accidental Ingestion; Neonatal Opioid Withdrawal Syndrome; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants; and Risk of Medication Errors (due to immediate-release formulation, which requires careful dose conversion from other oxycodone products).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients and those with pre-existing respiratory conditions.,Risk of opioid-induced hyperalgesia.,Adrenal insufficiency with prolonged use.,Severe hypotension, including orthostatic hypotension, in patients with compromised ability to maintain blood pressure.,Risk of serotonin syndrome with concomitant serotonergic drugs.,Seizures in patients with seizure disorders or taking other seizure threshold-lowering drugs.,Avoid abrupt discontinuation; taper dose to prevent withdrawal syndrome.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to oxycodone or any component of the formulation
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Avoid alcohol and any alcohol-containing foods or beverages. Grapefruit and grapefruit juice may increase oxycodone levels; avoid concurrent use.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Avoid during labor due to respiratory depression in the newborn.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Small amounts of oxycodone are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 3:1. Use with caution, especially in mothers who are ultrarapid metabolizers of CYP2D6, as this increases risk of toxicity in the infant. Monitor infant for drowsiness, poor feeding, and respiratory depression.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Pregnancy may increase oxycodone clearance due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed: consider increasing the frequency or dose based on pain control and tolerance. Avoid high doses near term; use lowest effective dose. Monitor for respiratory depression in both mother and neonate.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
ROXYBOND (oxycodone hydrochloride) is an immediate-release opioid agonist indicated for acute pain severe enough to require an opioid. Its unique formulation resists crushing and dissolution, but it can still be abused intravenously. Be aware of the risk of respiratory depression, particularly in opioid-naive patients. Use with caution in patients with respiratory disease, or in elderly or debilitated patients. Tolerance and dependence can develop; monitor for signs of misuse. Naloxone is the reversal agent. Not indicated for as-needed use; prescribe the lowest effective dose for the shortest possible duration.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Take exactly as prescribed; do not break, crush, chew, or dissolve the tablet as it can cause rapid release and fatal overdose.,Do not consume alcohol or any alcohol-containing products while taking ROXYBOND.,Store securely out of sight and reach of children and pets; properly dispose of unused tablets via a drug take-back program.,Side effects include constipation, nausea, dizziness, and drowsiness; contact your healthcare provider if you experience difficulty breathing or extreme sleepiness.,Avoid driving or operating heavy machinery until you know how ROXYBOND affects you.,Do not share this medication with others; it can cause addiction and death.,Inform your doctor about all other medications, especially sedatives, tranquilizers, or antidepressants.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXYBOND vs ALEVE, answered by our medical review team.
ROXYBOND is a Opioid Analgesic that works by ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXYBOND and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXYBOND is: Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXYBOND and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXYBOND is classified as Category C. ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chr. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.